Pharmaceutical manufacturers of Ursodiol

We are a Pharmaceutical Company aligned across two business verticals viz. Products and Services. Our Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both Domestic and International markets including the regulated markets.

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

Daewoong Bio Inc., a standalone affiliate of the Daewoong Group located in Seoul, South Korea, was established in 1983. Daewoong Bio manufactures world-class products that comply with cGMP standards under quality assurance systems. As a primary producer, Daewoong Bio supplies APIs for worldwide distribution and multinational enterprises developing innovative products. Daewoong Bio is also a comprehensive pharmaceutical company that employs its internal research and development, production facilities, and experienced marketing team along with external global connections. Daewoong Bio specializes in the production of top-notch antibiotic APIs and general APIs.

Adare Pharma Solutions is a global technology-driven CDMO providing product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical industry. Adare’s specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. With a proven history in drug delivery, Adare has developed and manufactured more than 65 products sold by customers in more than 100 countries globally.

Sichuan Xieli Pharmaceutical Co., Ltd. was founded in 1980 with the development concept of "Xieli Tongchuang Health Cause". It mainly engages in the cultivation of ecological medicinal materials, the extraction of natural active ingredients from animals and plants, and the synthesis and research of their derivatives. It is based on the production of high value-added export products. There are mainly dozens of varieties, including rutin based cardiovascular and cerebrovascular drugs, plant flavonoids based capillary drugs, plant derived anti-tumor drugs, animal and plant extracts, and pharmaceutical intermediates.

ICE Pharma's primary focus is on the production of active pharmaceutical ingredients, with Ursodeoxycholic Acid (UDCA) being the key component, utilized in the treatment of liver conditions and gallstones. The company specializes in creating a variety of bile acid derivatives that serve as excipients, nutraceutical ingredients, cell culture media, and intermediates. Additionally, ICE Pharma offers contract manufacturing services for both liquid and solid finished dosage forms, catering to branded and generic products. Advent International, a leading global private equity investor, has owned ICE Pharma since October 2019.

Established in 2004 with a registered capital of 66 million yuan, Zhongshan Belling Biotechnology Co.,Ltd. is situated in the National Health Technology Park within the Torch Development Zone of Zhongshan City, Guangdong Province. Operating as a sino·foreign joint venture, Belling has been recognized as a National High Technology Enterprise in 2009, 2012, 2015 and 201, honored with the Technology R&D Center for Animal Pharmaceutical Ingredients award in 2013, successfully achieved UDCA GMP certification in 2015, accredited as the Guangdong Provincial Enterprise Technology Center in May 2018, and obtained the CEP certificate from EDQM in August 2019.